Single‐agent nivolumab or atezolizumab treatments are now standard second‐line treatments, regardless of PD‐L1 status, as well as pembrolizumab for patients with a PD‐L1 tumor proportion score of ≥1%.1, 2, 3, 4 Pembrolizumab monotherapy is also approved as first‐line treatment for advanced NSCLC in patients with PD‐L1 expression of >50%, and this indication was recently extended to patients with PD‐L1 expression of ≥1%.5, 6. This evidence concerns the gene CD274 and neoplasm.